- 7			10,	Docket Number (Optional)	Application Number			
of the second				MST-2393 US	10/723,795			
	NO		TYON DISCLOSURE CITATION (Use giveral sheets if necessary)	Applicant(s) Supuran et al.				
/		1	Ose Revertil streets if necessial y	Filing Date	Group Art Unit			
8	FEB	0 9 20	.04 🐒	November 26, 2003				
*EXAMINI	.		£7 ·	tle, Date, Pertinent Pages, Etc.)				
	TRA	لتغفينا	Casini et al., "Carbonic Anhydrase Inhibitors: Wa Pressure-Lowering Agents with Long-Lasting Effe	ter-Soluble 4-Sulfamoylphenylthiourez ets," J. Med. Chem., 43: 4884-4892 (2)	as as Topical Intraocular 000)			
BF	'							
•			Chegwidden et al., "The Roles of Carbonic Anhydrand Proteins, Proceedings of the International Isoz (Xue, G. ed.; World Scientific Pub. Co.; 2001)	rase Isozymes in Cancer," Gene Famili ymes, 10th, Beijing, China, Oct. 5-10,	ies: Studies of DNA, RNA, Enzymes 1999, Meeting Date 1999, 157-169			
			Clare and Supuran, "Carbonic anhydrase iinhibito benzenedisulfonamides," <u>Eur. J. Med. Chem., 34</u> : 4	nhibitors. Part 61. Quantum chemical QSAR of a group of 1., 34: 463-474 (1999)				
***************************************			Cuthbert et al., "Bicarbonate-dependent chloride secretion in Calu-3 epithelia in response to 7,8-benzoquinoline," <u>J Physiol., 551</u> (Pt 1): 79-92 (2003 Aug 15)					
damananan			Franchi et al., "Carbonic Anhydrase Inhibitors. In Cancer-associated Isozyme IX with Lipophilic Sulf 333-338 (Aug. 2003)	hibition of Cytosolic Isozymes I and II onamides," <u>Journal of Enzyme Inhibit</u>	and Transmembrane, ion and Medicinal Chemistry, 18(4):			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Ilies et al., "Carbonic Anhydrase Inhibitors. Inhib Halogenophenylaminobenzolamide Derivatives," <u>J.</u>	ition of Tumor-Associated Isozyme IX . Med. Chem., 46: 2187-2196 (2003)	by Halogenosulfanilamide and			
		14.	Pastorek et al., "Cloning and characterization of M carbonic anhydrase and a putative helix-loop-helix	IN, a human tumor-associated protein DNA binding segment," Oncogene, 9:	with a domain homologous to 2877-2888 (1994)			
		1	Scozzafava and Supuran, "Carbonic Anhydrase Inhibitors: Synthesis of N-Morpholylthiocarbonylsulfenylamino Aromatic/Heterocyclic Sulfonamides and their Interaction with Isozymes I, II and IV," Bioorganic & Medicinal Chemistry Letters, 10: 1117-1120 (2000)					
		I	Scozzafava et al., "Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moieties: Is the Tail More Important than the Ring?" J. Med. Chem., 42: 2641-2650 (1999)					
			Scozzafava et al., "Carbonic Anhydrase Inhibitors: Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes," J. Med. Chem., 43: 292-300 (Jan. 27, 2000)					
			Sterling et al., "The functional and physical relatio II," Am. J. Physiol. Cell Physiol., 283(5): C1522-C	al., "The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase Physiol. Cell Physiol., 283(5): C1522-C1529 (Nov. 2002)				
BF			Supuran and Clare, "Carbonic anhydrase inhibitors. Part 24. A quantitative structure-activity relationship study of positively charged sulfonamide inhibitors," <u>Eur. J. Med. Chem., 30</u> : 687-696 (1995)					
EXAMINER /Brandon Fetterolf/			randon Fetterolf/	DATE CONSIDERED 5/11/2	2009			
				J/ ±±/ 2	.009			
			itation considered, whether or not citation is in conforms	ance with MPEP Section 609; Draw line the	rough citation if not in conformance and			

À.		Docket Number (Optional)	Application Number			
OIPE		MST-2393 US	10/723,795			
/ INFORM	ANON DISCLOSURE CITATION	Applicant(s)				
FED 0 0 20	(Use everal sheets if necessary)	Supuran et al.	Group Art Unit			
P FEB 0 9 20		Filing Date November 26, 2003	Group Art Omt			
*EXAMINER INITIAL DE AL	OTHER DOCUMENTS (Including Author, Title	le, Date, Pertinent Pages, Etc.)				
INTIAL CONTRACTOR	Supuran and Clare, "Carbonic anhydrase inhibitor 1,3,4-thiadiazoline disulfonamides with carbonic an	s - Part 57: Quantum chemical QSAR	of a group of 1,3,4-thiadiazole- and			
ВГ	1,5,4-thradiazonne disultonamides with carbonic an	nyurase minortory properties, <u>pure</u>	<u> </u>			
	Supuran and Scozzafava, "Carbonic Anhydrase Inhibitors: Aromatic Sulfonamides and Disulfonamides Act as Efficient Tumor Growth Inhibitors," J. Enzyme Inhib., 15(6): 597-610 (2000)					
	Supuran and Scozzafava, "Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?," Eur. J. Med. Chem., 35(9):867-874 (Sept. 2000)					
	Supuran et al., "Carbonic anhydrase inhibitors – Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV," Eur. J. Med. Chem., 33: 577-594 (1998)					
	Supuran et al., "Carbonic anhydrase inhibitors - Part 29: Interaction of isozymes I, II and IV with benzolamide-like derivatives," Eur. J. Med. Chem., 33: 739-751 (1998)					
	Supuran et al., "Carbonic Anhydrase Inhibitors: Synthesis of Sulfonamides Incorporating 2,4,6-Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and In Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes," J. Enzyme Inhibition, 15(4): 381-401 (2000)					
0	Supuran et al., "Carbonic Anhydrase Inhibitors: So 9(3): 703-714 (March 2001)	upuran et al., "Carbonic Anhydrase Inhibitors: Sulfonamides as Antitumor Agents?," <u>Bioorganic & Medicinal Chemistry,</u> (3): 703-714 (March 2001)				
9	Supuran et al., "Carbonic Anhydrase Inhibitors," [arbonic Anhydrase Inhibitors," <u>Medicinal Research Reviews, 2</u> 3(2): 146-189 (March 2003)				
	Teicher et al., "A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies," Anticancer Research, 13: 1549-1556 (1993)					
	Vullo et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Anions," <u>Journal of Enzyme Inhibition and Medicinal Chemistry</u> , 18(5): 403-406 (Oct. 2003)					
coccoccatannan	Vullo et al., "Carbonic Anhydrase Inhibitors: Inhibition of the Tumor-Associated Isozyme IX with Aromatic and Heterocyclic Sulfonamides," <u>Bioorganic Medicinal Chemistry Letters, 13(6)</u> : 1005-1009 (March 24, 2003)					
BF	Wingo et al., "The Catalytic Properties of Human Communications, 288: 666-669 (2001)	, "The Catalytic Properties of Human Carbonic Anhydrase IX," <u>Biochemical and Biophysical Research</u> tions, 288: 666-669 (2001)				
EXAMINER /E	Brandon Fetterolf/	DATE CONSIDERED 5/11/2	009			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and						

not considered. Include copy of this form with next communication to applicant.

. مند		Docket Number (Optional) MST-2393 US	Application Number			
100	drivation disclosure citation	Applicant(s)	10/723,795			
11.435	(Use everal sheets if necessary)	Supuran et al.				
	à	Filing Date	Group Art Unit			
	0 9 2004 15	November 26, 2003				
*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author	or, Title, Date, Pertinent Pages, Etc.)				
BF	OTHER DOCUMENTS (Including Authority) Winum et al., "Carbonic Anhydrase Inhibitor: Tumor-Associated Isozyme Ix with Sulfamates Chem., 46(11): 2197-2204 (May 22, 2003)	s. Inhibition of Cytosolic Isozymes I and s Including EMATE Also Acting as Stero	II and Transmembrane, id Sulfatase Inhibitors," <u>J. Med.</u>			
BF	Wistrand and Lindqvist, "Design of Carbonic Pharmacokinetics of Acetazolamide," In Carb Medicine, Botrè et al., Eds., VCH, Weinheim,	onic Anhydrase – From Biochemistry and	ip Between the Pharmacodynamics and a Genetics to Physiology and Clinical			
BF	Wu et al., Cytoplasmic pH Responses to Carbo Epithelium," <u>J. Membrane Biol., 162</u> : 31-38 (1	onic Anhydrase Inhibitors in Cultured Ra 1998)	abbit Nonpigmented Ciliary			
			200 - 200 -			
EXAMINER	/Brandon Fetterolf/	DATE CONSIDERED 5/11/2	2009			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and						

not considered. Include copy of this form with next communication to applicant.